Down 11% from Oct 9 to Oct 30 while the S&P 500 fell 3%.
−2Volatility
PGEN's Quality Score fell 5 points on Mon, Nov 2, to 4. Its 6-month gain fell to 24%, under 25.5%. 3 more reasons, for Pro members.
Follow PGEN's trial news. Pro members can get an alert when Precigen files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Moves 10.7% a day with no profit behind it |
| Latest filing | 10-Q, Aug 4 |
After its last 4 reports it closed +16.9% on average, higher 4 of 4 times.
About 1 quarter
Director Jeffrey B Kindler sold 185,000 shares on Aug 26. 15 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
PGEN is #33 of 92 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 33 |
Share count against a year before: PGEN +20%, ARWR +3.1%.
Reports Wed Nov 4, after the close (in 2 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“to the three months ended June 30, 2025, primarily due to the change in the accounting treatment of PAPZIMEOS manufacturing costs.”
PGEN's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“Cash, cash equivalents, and investments totaled $38.7 million as of June 30, 2026, which together with proceeds from PAPZIMEOS revenue, is expected to support cash flow break-even by the end of 2026”
From its results filing (SEC filing · Aug 4)
Its share count grew 13% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 4, 2026 | +7.5% | +5.5% | +5.0% |
| May 13, 2026 | +10.4% | +10.8% | +2.9% |
| Mar 25, 2026 | +31.1% | +25.5% | +26.8% |
Sales grew in two of the last seven years, to $9.7M in 2025. It made a profit in one of the eight years.
One insider bought $25K across 1 filing, and 6 insiders sold $2.5M across 6 filings, in the last 6 months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: PGEN is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
“While we believe that our novel approach to developing innovative precision medicines utilizing our AdenoVerse and UltraCAR-T platforms to target the most urgent and intractable challenges in immuno-oncology, autoimmune disorders, and infectious diseases provides us with competitive advantages, our industry is highly competitive and subject to rapid and significant technological change.”
PGEN scores 4 today, which Breakaway calls Below Average. It is #33 of 92 in Pharma by Quality Score, with 2 of 14 chart checks firing. Down 11% from Oct 9 to Oct 30 while the S&P 500 fell 3%. Cash lasts about 1 quarter at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
PGEN scores 4 today, which Breakaway calls Below Average (0 to 5). That is #33 of 92 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PGEN's 4.
One insider bought $25K across 1 filing, and 6 insiders sold $2.5M across 6 filings, in the last 6 months. The newest is Jeffrey B. Kindler, Director, who sold $1.4M on Aug 26. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.